DNV Accelerates FAMID Biomedical's Path to IVDR Certification in Record Time
DNV Accelerates FAMID Biomedical's Path to IVDR Certification
In a remarkable achievement for both DNV and FAMID Biomedical Technology, the EU Notified Body has successfully issued an IVDR certification to FAMID for their innovative diagnostic test aimed at aiding the early detection of cervical cancer. This certification process, which typically can take much longer, was completed in an impressive six months, showcasing a well-prepared approach from the manufacturer as well as effective collaboration with DNV.
The certification of the E7 Oncoprotein Rapid Test Kit, classified as a Class C In Vitro Diagnostic (IVD) device under the In Vitro Diagnostic Medical Devices Regulation (IVDR), is critical for FAMID Biomedical. The rapid test kit plays a vital role in diagnosing cervical epithelial cell lesions by detecting the HPV E7 oncoprotein from cervical cell samples. Its versatility allows for both professional laboratory usage and self-testing by individuals, fostering broader access to vital healthcare solutions.
Jim Miao, CEO of FAMID Biomedical Technology, expressed his satisfaction with the collaboration, stating that working with a certification partner who understands the importance of market access is invaluable for bringing medical technologies to the market swiftly. His affirmations were bolstered by DNV's professionalism, technical expertise, and collaborative spirit that guided FAMID through this complex certification journey.
Cecilie Gudesen Torp, the Managing Director of Medical Technologies at DNV, highlighted that achieving IVDR certification merely six months post-contract signing illustrates FAMID Biomedical’s readiness and the close cooperation between teams involved. The IVDR imposes more stringent requirements for diagnostic manufacturers than previous regulations, hence the accomplishment not only signifies FAMID's preparedness but also the specialized expertise and effective project management that DNV brought to the table.
DNV’s global Medical Technologies organization is committed to empowering manufacturers to navigate the complexities of the IVDR landscape. With a growing portfolio of international IVD manufacturers, DNV combines local customer engagement with specialized regulatory knowledge to support timely and effective market entry. This collaboration represents a significant step forward in ensuring that innovative diagnostic technologies reach those in need promptly, particularly in the European market.
FAMID's development of the E7 Oncoprotein Rapid Test Kit exemplifies how innovation in medical technology can address critical healthcare challenges such as cervical cancer diagnosis, enhancing the ability of healthcare providers to make informed decisions and improve patient outcomes. The swift certification by DNV not only paves the way for FAMID to expand its influence in the European marketplace but stands as a testament to the potential of well-coordinated partnerships in the medical sector.
In a future where timely access to diagnostics could mean the difference between early intervention and delayed treatment, FAMID’s newly certified diagnostic testing solution shines as a beacon of progress in the continuous battle against cervical cancer and highlights the pivotal role of certification bodies like DNV in transforming healthcare capabilities.
This achievement not only strengthens the position of FAMID within the market but emphasizes the critical importance of robust quality management systems, clinical evidence, and thorough technical documentation in smoothing the pathway toward compliance and success in healthcare innovation.